[CAS NO. 24584-09-6] Dexrazoxane

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [24584-09-6]

Catalog

HY-B0581

Brand

MCE

CAS

24584-09-6

DESCRIPTION [24584-09-6]

Overview

MDL	MFCD00866449
Molecular Weight	268.27
Molecular Formula	C11H16N4O4
SMILES	C[C@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Dexrazoxane (ICRF-187) is a cardioprotective agent. Target: Others Dexrazoxane is a cardioprotective agent. Dexrazoxane is a derivative of EDTA, dexrazoxane chelates iron and thus reduces the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals. The exact chelation mechanism is unknown, but it has be postulated that dexrazoxane can be converted into ring-opened form intracellularly and interfere with iron-mediated free radical generation that is in part thought to be responsible for anthryacycline induced cadiomyopathy. It was speculated that dexrazoxane could be used for further investigation to synthesize new antimalarial drugs [1, 2].

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03589729	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Myeloid Leukemia\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Blasts 10 Percent or More of Bone Marrow Nucleated Cells\|High Risk Myelodysplastic Syndrome\|Myeloid Sarcoma\|Myeloproliferative Neoplasm\|Philadelphia Chromosome Positive	September 19, 2018	Phase 2
NCT03930680	University of Arkansas	Healthy	June 1, 2021	Phase 1
NCT00165087	Dana-Farber Cancer Institute\|Boston Children´s Hospital	Acute Lymphoblastic Leukemia	January 1996	Phase 3
NCT04293562	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Myeloid Leukemia	July 20, 2020	Phase 3
NCT00005578	Children´s Oncology Group\|National Cancer Institute (NCI)	Cardiac Toxicity\|Lymphoma	March 1997	Phase 3
NCT03126916	Children´s Oncology Group\|National Cancer Institute (NCI)	Ganglioneuroblastoma\|Neuroblastoma	May 9, 2018	Phase 3
NCT01871766	St. Jude Children´s Research Hospital	Rhabdomyosarcoma	December 4, 2013	Phase 2
NCT00742924	Children´s Oncology Group\|National Cancer Institute (NCI)	Sarcoma	August 2008	Phase 1
NCT02953184	Jilin University	Antineoplastic Combined Chemotherapy Protocols	November 2016	Phase 2
NCT01627938	PD Dr. Andrew Chan\|Ruhr University of Bochum	Multiple Sclerosis	April 2012	Phase 2
NCT00038142	M.D. Anderson Cancer Center	Ewing´s Sarcoma	November 1997	Phase 2
NCT00334867	Children´s Oncology Group\|National Cancer Institute (NCI)	Sarcoma	December 2005	Phase 3
NCT00933985	National Cancer Institute (NCI)	Acute Leukemias of Ambiguous Lineage\|Acute Undifferentiated Leukemia\|Angioimmunoblastic T-cell Lymphoma\|Blastic Phase Chronic Myelogenous Leukemia\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK+T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent+Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Small Intestine Lymphoma\|Unspecified Childhood Solid Tumor, Protocol Specific	June 2009	Phase 1
NCT01523977	Dana-Farber Cancer Institute\|Novartis	Acute Lymphoblastic Leukemia	November 2011	Phase 1
NCT03007147	Children´s Oncology Group\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia\|Mixed Phenotype Acute Leukemia\|T Acute Lymphoblastic Leukemia	July 28, 2017	Phase 3
NCT00544778	City of Hope Medical Center\|National Cancer Institute (NCI)	Sarcoma	August 2001	Phase 2
NCT01230983	Children´s Oncology Group\|National Cancer Institute (NCI)	Cardiac Toxicity\|Leukemia\|Lymphoma	June 1996	Phase 3
NCT00400946	Dana-Farber Cancer Institute\|National Cancer Institute (NCI)	Drug+Agent Toxicity by Tissue+Organ\|Leukemia	April 2005	Phase 3
NCT00016276	National Cancer Institute (NCI)	Cardiac Toxicity\|Inflammatory Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IV Breast Cancer	May 2001	Phase 3
NCT01864109	Memorial Sloan Kettering Cancer Center	Newly Diagnosed Ewing Sarcoma	May 2013	Phase 2
NCT00980460	National Cancer Institute (NCI)	PRETEXT Stage 1 Hepatoblastoma\|PRETEXT Stage 2 Hepatoblastoma\|PRETEXT Stage 3 Hepatoblastoma\|PRETEXT Stage 4 Hepatoblastoma	September 14, 2009	Phase 3
NCT00955890	Fudan University	Breast Cancer	June 2009	Phase 2
NCT01258634	University of Chicago	Osteosarcoma\|Lung Metastases	July 2010	Phase 1
NCT00019864	National Cancer Institute (NCI)	Cardiac Toxicity\|Sarcoma	March 2000	Phase 2
NCT00003937	Children´s Oncology Group\|National Cancer Institute (NCI)	Cardiac Toxicity\|Sarcoma	September 1999	Phase 3
NCT00039481	National Cancer Institute (NCI)	Cardiac Toxicity\|Unspecified Childhood Solid Tumor, Protocol Specific	November 2002	Phase 1
NCT00550901	City of Hope Medical Center\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	February 2001	Phase 1
NCT04997291	University of Texas at Austin\|Dell Children´s Medical Center of Central Texas	Heart Defects, Congenital	April 9, 2021	Phase 1
NCT01596088	Kissei Pharmaceutical Co., Ltd.	Extravasations of Anthracycline Anti-cancer Agents		Phase 1\|Phase 2
NCT02584309	Washington University School of Medicine	Sarcoma, Soft Tissue\|Soft Tissue Sarcoma\|Undifferentiated Pleomorphic Sarcoma\|Leiomyosarcoma\|Liposarcoma\|Synovial Sarcoma\|Myxofibrosarcoma\|Angiosarcoma\|Fibrosarcoma\|Malignant Peripheral Nerve Sheath Tumor\|Epithelioid Sarcoma	February 22, 2016	Phase 2
NCT00002827	Children´s Oncology Group\|National Cancer Institute (NCI)\|Children´s Cancer Group	Cardiac Toxicity\|Lymphoma	October 1996	Phase 3
NCT01606878	Children´s Oncology Group\|National Cancer Institute (NCI)	Childhood Solid Neoplasm\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Neuroblastoma	April 29, 2013	Phase 1
NCT00548704	Onxeo	Extravasation	April 2002	Phase 2\|Phase 3
NCT01231906	Children´s Oncology Group\|National Cancer Institute (NCI)	Localized Extraskeletal Ewing Sarcoma\|Peripheral Primitive Neuroectodermal Tumor of Bone\|Peripheral Primitive Neuroectodermal Tumor of Soft Tissues	November 22, 2010	Phase 3
NCT00001335	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Ewing´s Sarcoma\|Neuroblastoma\|Rhabdomyosarcoma	April 1993	Phase 2
NCT03786783	National Cancer Institute (NCI)	Ganglioneuroblastoma\|High Risk Neuroblastoma	January 14, 2019	Phase 2
NCT03698227	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Advanced Soft Tissue Sarcoma	November 12, 2018	Phase 2
NCT02519335	Medical City Children´s Hospital\|Mylan Pharmaceuticals Inc	Heart Defects, Congenital	September 2014	Phase 1
NCT00928200	Therapeutic Advances in Childhood Leukemia Consortium	Relapsed Acute Lymphoblastic Leukemia\|Allergy to PEG e.Coli Asparaginase\|Allergy to Native e.Coli Asparaginase	April 13, 2009	Phase 1
NCT03164057	St. Jude Children´s Research Hospital	Acute Myeloid Leukemia\|Myelodysplastic Syndromes	June 15, 2017	Phase 2
NCT00410488	M.D. Anderson Cancer Center\|Eisai Inc.	Sarcoma\|Nausea\|Vomiting	December 2006	Not Applicable
NCT00077285	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Sarcoma	October 2003	Phase 2
NCT00548561	Onxeo	Anthracycline Extravasation	June 2001	Phase 2\|Phase 3
NCT00003667	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Sarcoma	September 1998	Phase 2
NCT00673179	M.D. Anderson Cancer Center	Osteosarcoma	May 2008	Not Applicable
NCT00098839	Children´s Oncology Group\|National Cancer Institute (NCI)	Recurrent Childhood Acute Lymphoblastic Leukemia	February 2005	Phase 1\|Phase 2
NCT03020030	Dana-Farber Cancer Institute\|Servier	Acute Lymphoblastic Leukemia, Pediatric	March 3, 2017	Phase 3
NCT05292664	Andrew E. Place\|AbbVie\|Servier\|Children´s Cancer Research Fund\|University of Colorado, Denver\|Boston Children´s Hospital\|Dana-Farber Cancer Institute	Myelodysplastic Syndromes, de Novo\|Myelodysplastic Syndromes, Secondary\|Myelodysplastic Syndromes, Previously Treated\|Treatment-Related Acute Myeloid Leukemia\|Therapy-Related Myelodysplastic Syndrome\|Acute Lymphoblastic Leukemia, in Relapse\|Acute Lymphoblastic Leukemia With Failed Remission\|Lymphoblastic Lymphoma, in Relapse\|Lymphoblastic Lymphoma, Refractory\|Acute Leukemia of Ambiguous Lineage in Relapse\|Acute Leukemia of Ambiguous Lineage Not Having Achieved Remission	October 2022	Phase 1
NCT00084838	Dana-Farber Cancer Institute\|National Cancer Institute (NCI)	Central Nervous System Tumor, Pediatric	February 2003	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL ( 93.19 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.7276 mL	18.6379 mL	37.2759 mL
5 mM	0.7455 mL	3.7276 mL	7.4552 mL
10 mM	0.3728 mL	1.8638 mL	3.7276 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

2,6-Piperazinedione, 4,4′-[(1S)-1-methyl-1,2-ethanediyl]bis-

2,6-Piperazinedione, 4,4′-propylenedi-, (+)-

2,6-Piperazinedione, 4,4′-(1-methyl-1,2-ethanediyl)bis-, (S)-

4,4′-[(1S)-1-Methyl-1,2-ethanediyl]bis[2,6-piperazinedione]

(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane

ICRF 187

NSC 169780

(S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane

Dexrazoxane

ADR 529

(S)-4,4′-(Propane-1,2-diyl)bis(piperazine-2,6-dione)